Wasp Venom Peptide Shows Unexpected Anti-Malaria and Anti-Cancer Activity
The wasp venom peptide polybia-CP and its redesigned derivatives kill malaria parasites and cancer cells, with helical structure and positive charge driving antimalarial potency.
Quick Facts
What This Study Found
Polybia-CP derivatives with optimized helicity and charge show potent antiplasmodial and anticancer activity while having reduced general toxicity compared to the wild-type peptide.
Key Numbers
Submicromolar antiplasmodial potency; micromolar anticancer; helicity + charge drive activity; hydrophobicity needed for cancer
How They Did This
Physicochemical-guided peptide design, antiplasmodial activity against Plasmodium sporozoites, cancer cell killing assays, structure-activity analysis.
Why This Research Matters
Malaria kills hundreds of thousands annually and drug resistance is growing. Antimicrobial peptides with antiplasmodial activity represent a new drug class with a different mechanism of action.
The Bigger Picture
This study reveals that antimicrobial peptides may have broader biological activities than originally recognized, opening new applications in infectious disease and oncology.
What This Study Doesn't Tell Us
In vitro activity data only. Selectivity between parasite/cancer cells and host cells needs further optimization. No in vivo efficacy data.
Questions This Raises
- ?Can polybia-CP derivatives be optimized for safe in vivo antimalarial use?
- ?What is the mechanism of action against Plasmodium sporozoites?
- ?Could these peptides complement existing antimalarial drugs?
Trust & Context
- Key Stat:
- Dual activity Wasp venom peptide derivatives kill both malaria parasites and cancer cells while having reduced toxicity
- Evidence Grade:
- In vitro proof-of-concept demonstrating new biological activities. Early discovery stage.
- Study Age:
- Published in 2020. Antimicrobial peptides as antimalarials is a relatively new research direction.
- Original Title:
- The wasp venom antimicrobial peptide polybia-CP and its synthetic derivatives display antiplasmodial and anticancer properties.
- Published In:
- Bioengineering & translational medicine, 5(3), e10167 (2020)
- Authors:
- Torres, Marcelo D T(6), Silva, Adriana F, Andrade, Gislaine P, Pedron, Cibele N, Cerchiaro, Giselle, Ribeiro, Anderson O, Oliveira, Vani X, de la Fuente-Nunez, Cesar
- Database ID:
- RPEP-05169
Evidence Hierarchy
Frequently Asked Questions
How can a wasp venom peptide fight malaria?
Antimicrobial peptides interact with cell membranes. Malaria parasites (Plasmodium sporozoites) have membrane properties that make them vulnerable to these peptides. The researchers found that peptides with the right balance of helical shape and positive charge are particularly effective.
Why redesign the original wasp venom peptide?
The natural peptide polybia-CP is effective but also highly toxic to healthy cells. By modifying its sequence, researchers reversed the toxicity while preserving and even enhancing its antimicrobial, antimalarial, and anticancer properties.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05169APA
Torres, Marcelo D T; Silva, Adriana F; Andrade, Gislaine P; Pedron, Cibele N; Cerchiaro, Giselle; Ribeiro, Anderson O; Oliveira, Vani X; de la Fuente-Nunez, Cesar. (2020). The wasp venom antimicrobial peptide polybia-CP and its synthetic derivatives display antiplasmodial and anticancer properties.. Bioengineering & translational medicine, 5(3), e10167. https://doi.org/10.1002/btm2.10167
MLA
Torres, Marcelo D T, et al. "The wasp venom antimicrobial peptide polybia-CP and its synthetic derivatives display antiplasmodial and anticancer properties.." Bioengineering & translational medicine, 2020. https://doi.org/10.1002/btm2.10167
RethinkPeptides
RethinkPeptides Research Database. "The wasp venom antimicrobial peptide polybia-CP and its synt..." RPEP-05169. Retrieved from https://rethinkpeptides.com/research/torres-2020-the-wasp-venom-antimicrobial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.